Figure Figure 1.

(A) Least‐squares (LS) mean between‐treatment differences (zoledronic acid vs. placebo) in the percentage change in total hip BMD at 12 mo by timing of first study drug infusion after hip fracture repair. (B) LS mean between‐treatment differences (zoledronic acid vs. placebo) in the percentage change in total hip BMD at 24 mo by timing of first study drug infusion after hip fracture repair. (C) Hazard ratios (HRs) for reductions in clinical fractures by timing of first study drug infusion.^† (D) HR for reductions in nonvertebral fractures by timing of first study drug infusion.^† (E) HR for reductions in hip fractures by timing of first study drug infusion.^† (F) HR for reductions in clinical vertebral fractures by timing of first study drug infusion.^† (G) HR for reductions in death by timing of first study drug infusion.^† *p < 0.05; **p < 0.01; ***p < 0.001. ^†Significance determined based on log‐rank test.